Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial

Table 2 Part 2. Baseline clinical data of controlled study (n = 50)

Variables	Tranexamic acid (n = 24)	Placebo (n = 26)	P value
Demographic
Age, years	66 (63–70)	67 (62–71)	0.91
Male gender, number (percentage)	12 (50)	15 (57)	0.58
Body mass index, kg/m²	28 (25.8–30.1)	28.1 (36.4–29.7)	0.98
Parsonnet score	13.1 (11.8–15.5)	17.5 (13.7–21.3)	0.07
Comorbidity
Cardiopathy, number (percentage)
Coronary	13 (54)	12 (46)	0.71
Valve	9 (38)	10 (39)	0.68
Mixed	2 (8)	4 (15)	0.44
Medical treatment
Angiotensin-converting enzyme inhibitors, number (percentage)	11 (61)	7 (39)	0.16
Calcium channel blockers, number (percentage)	6 (60)	4 (40)	0.39
Preoperative parameters
Platelet count, × 10³/mL	210 (186–234)	210 (186–239)	0.68
Hemoglobin, g/dL	14.1 (13.5–14.6)	13.6 (12.8–14.4)	0.42
International normalized ratio	1.08 (1.05–1.12)	1.09 (1.05–1.14)	0.97
D-dimer, ng/mL	250 (166–333)	275 (215–325)	0.34
Plasminogen activator inhibitor 1, ng/mL	34.2 (29–39.5)	35.2 (29.4–41.1)	0.95
Surgical data
Cardiopulmonary bypass time, minutes	82 (71–94)	85 (74–96)	0.30
Aortic clamping time, minutes	51 (44–58)	55 (47–62)	0.35
Temperature after cardiopulmonary bypass, degrees Celsius	35.3 (34.9–35.6)	35.1 (34.7–35.3)	0.24
Total heparin dose, UI/kg	430 (400–470)	420 (400–440)	0.69
Total protamine dose, mg/kg	2.7 (2.5–3)	2.7 (2.6–2.9)	0.72
Blood salvage device, mL	681 (605–756)	764 (694–833)	0.12

Values are expressed as mean and 95% confidence interval or as frequency and percentage.

ISSN: 1364-8535